ARTICLE | Clinical News
Jardiance empagliflozin: Phase III data
August 24, 2015 7:00 AM UTC
Top-line data from the double-blind, international Phase III EMPA-REG OUTCOME trial in about 7,097 Type II diabetics at a high risk for CV events showed that Jardiance plus standard of care (SOC) met ...